Inflow vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 38)
Inflow logo

Inflow

EmergingHealthcare

General

London ADHD management app with CBT and coaching for adults managing ADHD without relying solely on medication; $16.7M Octopus Ventures Series A with 100K+ downloads competing with Done and Cerebral.

AI VisibilityBeta
Overall Score
D38
Category Rank
#462 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
37
Gemini
40

About

Inflow is a London-based digital health company providing a science-based self-management app for adults with ADHD — backed with $16.7 million raised including an $11 million Series A led by Octopus Ventures in 2023 — delivering cognitive behavioral therapy (CBT), psychoeducation, ADHD coaching, and evidence-based habit management tools through a mobile app that helps adults understand and manage their ADHD without relying exclusively on medication. Founded in 2020, Inflow acquired Lina Health in 2022 to expand telehealth capabilities and has achieved 100,000+ downloads, serving adults who are newly diagnosed, managing ADHD alongside medication, or seeking non-pharmacological coping strategies.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

38
Overall Score
93
#462
Category Rank
#1
81
AI Consensus
80
stable
Trend
up
36
ChatGPT
94
37
Perplexity
89
40
Gemini
94
39
Claude
92
44
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.